| scholarly article | Q13442814 |
| P50 | author | Ainsley Weston | Q28037208 |
| Channa Keshava | Q28050523 | ||
| Miriam C. Poirier | Q107022221 | ||
| P2093 | author name string | Vikram Arora | |
| Clifford Pereira | |||
| Brinda Mahadevan | |||
| William M. Baird | |||
| Patrick L. Iversen | |||
| Laura J. Schild | |||
| Melissa L. Cate | |||
| P2860 | cites work | Expression monitoring by hybridization to high-density oligonucleotide arrays | Q27860473 |
| Morpholino antisense oligomers: design, preparation, and properties | Q28243074 | ||
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes | Q28576392 | ||
| Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. | Q33389761 | ||
| Morpholino antisense oligomers: the case for an RNase H-independent structural type | Q33901587 | ||
| Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation | Q34064082 | ||
| Understanding the genotoxicity of tamoxifen? | Q34263249 | ||
| Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. | Q35194482 | ||
| Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells | Q41590943 | ||
| Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts | Q42059552 | ||
| The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. | Q42163644 | ||
| DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation | Q42279753 | ||
| Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays | Q43592455 | ||
| Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. | Q43746671 | ||
| Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen | Q43750888 | ||
| Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats | Q43918589 | ||
| Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats | Q43956131 | ||
| Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes | Q43998853 | ||
| Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism | Q44028559 | ||
| Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer | Q44717416 | ||
| Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization | Q45875326 | ||
| Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. | Q48274353 | ||
| Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. | Q48558314 | ||
| Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. | Q53407664 | ||
| Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. | Q53472390 | ||
| A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. | Q53473784 | ||
| Risk of endometrial cancer after tamoxifen treatment of breast cancer | Q57307349 | ||
| Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial | Q72677675 | ||
| Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen | Q73108097 | ||
| Tamoxifen-DNA adducts formed by alpha-acetoxytamoxifen N-oxide | Q73187898 | ||
| Drug target validation and identification of secondary drug target effects using DNA microarrays | Q77534975 | ||
| Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA | Q77834357 | ||
| P6195 | funding scheme | extramural research | Q124503498 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| tamoxifen | Q412178 | ||
| exposure assessment | Q4008388 | ||
| DNA adducts | Q4153410 | ||
| P5008 | on focus list of Wikimedia project | Wikimedia–NIOSH collaboration | Q104416361 |
| P304 | page(s) | 118-125 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Molecular Carcinogenesis | Q15724597 |
| P859 | sponsor | NIOSH Health Effects Laboratory Division | Q123344455 |
| NIOSH Respiratory Health Division | Q123344459 | ||
| P1476 | title | Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology | |
| P478 | volume | 45 |
| Q35086803 | An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride. |
| Q37511330 | Is tamoxifen a genotoxic carcinogen in women? |
| Q47593390 | Liver Genes Expression Induced by Tamoxifen Loaded Solid Lipid Nanoparticles in Wistar Female Rats |
| Q54215891 | Molecular insights into the association of obesity with breast cancer risk: relevance to xenobiotic metabolism and CpG island methylation of tumor suppressor genes. |
Search more.